NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE American · Biotechnology · USD

IGC Pharma, Inc. (IGC) Stock Analysis

IGC Pharma, Inc. (IGC) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.

IGC

$0.30

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IGC with… →

IGC Key Statistics

As of Sep 4, 2026
Trading
Open
$0.30
Previous Close
$0.30
52-Week Range
0.24–0.45
Volume
372.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.49
Valuation
Market Cap
$30.81M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
27.86
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.06
Financials (FY)
Revenue (FY)
$1.27M−5.50%
Net Income (FY)
−$7.12M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
103.38M
1-Year Return
−31.82%
Dividend and dates
Avg Volume
680.03K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

IGC Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+7.14%
2025−17.65%
2024+21.43%
2023−12.50%
2022−67.35%
2021−37.18%
2020+147.62%
2019+125.00%
2018−72.00%
2017+257.14%
2016 (partial year)−47.17%

As of September 4, 2026.

IGC Revenue and Earnings by Fiscal Year

FY ends March
Fiscal yearRevenueNet incomeNet margin
2024$1.27M−$7.12M−560.3%
2023$1.35M−$13.00M−966.5%
2022$911.00K−$11.51M−1263.0%
2021$397.00K−$15.02M−3782.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2024$1.27M$619.00K−$7.45M−$7.12M−560.3%
2023$1.35M$733.00K−$9.80M−$13.00M−966.5%
2022$911.00K$442.00K−$11.57M−$11.51M−1263.0%
2021$397.00K$194.00K−$15.43M−$15.02M−3782.4%

Annual figures as reported, in the company's reporting currency. As of March 31, 2025.

IGC Valuation vs Biotechnology Median

Median of 656 stocks
MetricIGCBiotechnology medianvs median
P/S ratio27.8615.2682% above
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

IGC Pharma, Inc. (IGC) is capitalised at $30.81M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 70 employees.

The 52-week range on file runs from $0.24 to $0.45. The most recent close on file for IGC is $0.30, dated September 4, 2026. The close was unchanged from the previous session. The latest close sits 25% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2024, shows revenue of $1.27M. Against the prior fiscal year total of $1.35M, that is a change of −5.50%. The same year closed with a net loss of $7.12M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −0.06.

Across the 4 fiscal years on file, revenue moves from $397.00K in 2021 to $1.27M in 2024. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 27.86. On price-to-sales that is 82.5% above the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is −31.82%. Across 10 years the annualized return works out at −3.08%. Beta against the wider market is reported at 0.49. Annualized volatility over the trailing 10 years is 209.12%.

Growth & Income

No dividend is on file for IGC.

So far in 2026 the price is +7.14%. The strongest complete calendar year on file is 2017 at +257.14%; the weakest is 2018 at −72.00%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

IGC Pharma, Inc. (IGC) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
IGC Pharma, Inc. IGC $30.81M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. IGC Pharma, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About IGC Pharma, Inc.

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.

Visit website →